New Covid-19 test and a decent first quarter buoy Abbott
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.
$1bn Corindus deal gets Healthineers off the acquisition blocks
Vascular robotics is growing fast and Corindus is the leader here, but Healthineers will need an aggressive sales plan.
Sanofi needs more success stories for its ‘good news’ division
Sanofi needs more than Dupixent for its speciality care division to remain a bright spot.
Novartis joins Pfizer and J&J in putting on pricing brakes
Novartis is the latest big pharma company to pledge not to increase drug prices. But does this signal a shift in the industry?
Could big biotech succumb to the urge to merge?
With growth stalling at some of the industry's biggest biotechs is it time to take a leaf out of big pharma's M&A playbook?
Philips uses its intelligence for outcomes-based incomes
Philips prioritises artificial intelligence-based technologies as it seeks to grow its Connected Care and Health Informatics unit
